Chemical formula: C₁₇H₂₅NO₃ Molecular mass: 291.385 g/mol PubChem compound: 2905
Cyclopentolate interacts in the following cases:
The effects of anti-muscarinic agents may be enhanced by the concomitant administration of other drugs with antimuscarinic properties such as some antihistamines, butyrophenones, phenothiazines, tricyclic antidepressants and amantadine.
Cyclopentolate should be used with caution in children with known epilepsy.
There is insufficient evidence as to drug safety in pregnancy. This product should not be used during pregnancy unless it is considered essential by a physician.
There is insufficient evidence as to drug safety in lactation.
May cause blurred vision, difficulty in focusing and sensitivity to light. Patients should be warned not to drive or engage in other hazardous activities (including climbing ladders and scaffolding) unless vision is clear. Complete recovery from the effects of cyclopentolate eye drops may take up to 24 hours.
Frequencies are defined according to the following convention: very common (≥1/100), common ≥1/100 to 1/10, uncommon ≥1/1,000 to <1/100, rare (≥11/10,000 to <1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
| System organ class | Adverse reactions | Frequency |
|---|---|---|
| Psychiatric disorders | abnormal behavioura, psychotic disordersa | not known |
| Nervous system disorders | dizziness, convulsionsb, partial seizuresb | not known |
| Eye disorders | eye pain, increased intraocular pressure, eye oedema1, eye irritation (stinging)1, ocular hyperaemia1, conjunctivitis1, photophobia2 | not known |
| Cardiac disorders | bradycardia, tachycardia, palpitations, arrhythmia, cardiopulmonary failurea | not known |
| Vascular disorders | flushing | not known |
| Gastrointestinal disorders | dry mouth, vomiting, gastrointestinal hypomotility and constipation, abdominal distensionc, necrotising enterocolitisd | not known |
| Skin and subcutaneous disorders | dry skin, skin rasha | not known |
| Renal and urinary disorders | urinary urgency, urinary retention, dysuria | not known |
| General disorders and administration site conditions | gait disturbance | not known |
Notes:
General
1 Following prolonged administration
2 Secondary to pupillary dilation
Paediatric population
a Abnormal behaviour, psychotic disorders, cardiopulmonary failure and skin rashes have been reported in the paediatric population.
b Convulsions and partial seizures have been reported in children, although the cases reported to date have been low in number or isolated.
c Cases of abdominal distension have been reported in infants.
d Necrotising enterocolitis has been reported in preterm infants.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
